Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination
www.nature.com
external-link

Viruses expressing tumour antigens can prime and boost anti-tumour immunity but the efficiency of this approach depends on the capacity of the virus to infect the host. Here, the authors show that vaccination with oncolytic viruses co-administered with tumour antigenic peptides is as efficient as antigen-engineered oncolytic viruses.

Subscribe to see new publications and popular science coverage of current research on your homepage


  • 0 users online
  • 2 users / day
  • 14 users / week
  • 34 users / month
  • 112 users / 6 months
  • 1664 subscribers
  • 357 Posts
  • 235 Comments
  • Modlog